Gut

Response to ‘Rectal versus colonic submucosal cancer rates and procedural outcomes in large non-pedunculated polyps: French ESD registry data’

We read with great interest the study by Van der Voort et al ,1 which compared rectal versus colonic submucosal cancer rates ...
GutOpinion

Red cells, red flags: are we harming stable patients with outdated transfusion thresholds?

The 2022 UK-wide acute upper gastrointestinal bleeding (AUGIB) audit by Nigam and colleagues is a landmark. With ...
gut.bmj

Multiomics- and artificial intelligence-powered research platforms for enhancing understanding and prediction of the cholangiocarcinoma patient journey

The main purposes of research in cholangiocarcinoma (CCA) are prevention, early diagnosis and the development of effective therapies tailored to each patient’s clinical course and general condition.1 ...
gut.bmj

Functional bowel disorders and functional abdominal pain

The Rome diagnostic criteria for the functional bowel disorders and functional abdominal pain are used widely in research and practice. A committee consensus approach, including criticism from ...
gut.bmj

Fibrosis in IBD: from pathogenesis to therapeutic targets

Background Intestinal fibrosis resulting in stricture formation and obstruction in Crohn’s disease (CD) and increased wall stiffness leading to symptoms in ulcerative colitis (UC) is among the largest ...
gut.bmj

Alterations of gut microbiome in autoimmune hepatitis

Objective The significance of the liver-microbiome axis has been increasingly recognised as a major modulator of autoimmunity. The aim of this study was to take advantage of a large well-defined ...
gut.bmj

Early management of acute severe UC in the biologics era: development and international validation of a prognostic clinical index to predict steroid response

Objectives We aimed to determine whether changes in acute severe colitis (ASC) management have translated to improved outcomes and to develop a simple model predicting steroid non-response on ...
gut.bmj

Yin Yang 1 promotes hepatic steatosis through repression of farnesoid X receptor in obese mice

1 Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrinology and Metabolism, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China 2 Genomic ...
gut.bmj

COVID-19 and liver disease

Knowledge on SARS-CoV-2 infection and its resultant COVID-19 in liver diseases has rapidly increased during the pandemic. Hereby, we review COVID-19 liver manifestations and pathophysiological aspects ...
gut.bmj

Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification

Dr L Lundell, Department of Surgery, Sahlgrenska University Hospital, S-413 45 Göteborg, Sweden. BACKGROUND Endoscopic oesophageal changes are diagnostically helpful and identify patients exposed to ...
gut.bmj

Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease

19 Department of Gastroenterology and Hepatology, Singapore General Hospital, Singapore 24 Center for Digestive Diseases Research and Clinical Translation of Shanghai Jiao Tong University, Shanghai, ...
gut.bmj

Reconsidering statins in MASLD: beyond cardiovascular protection to multisystem benefit

We thank Dr Amjad and Dr Thomas for their interest in our recent study on statin use in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).1 2 Their letter raises several ...